[6]
Khakh BS. Astrocyte–Neuron interactions in the striatum: Insights on identity, form, and function. Trends in Neurosciences 2019; 42: 617-30.
[15]
Li F, Zhang B, Duan S, et al. Small dose of L-dopa/Benserazide hydrochloride improved sepsis-induced neuroinflammation and long-term cognitive dysfunction in sepsis mice. Brain Res 2020; 1737: 146780.
[18]
Broome ST, Louangaphay K, Keay K, Leggio G, Musumeci G, Castorina A. Dopamine: An immune transmitter. Neural Regen Res 2020; 15: 2173-85.
[28]
Xia QP, Cheng ZY, He L. The modulatory role of dopamine receptors in brain neuroinflammation. Int Immunopharmacol 2019; 76: 105908.
[32]
Millan MJ, Dekeyne A, Gobert A, et al. Dual-acting agents for improving cognition and real-world function in Alzheimer’s disease: Focus on 5-HT6 and D3 receptors as hubs. Neuropharmacology 2020; 177: 108099.
[48]
Tsang J, Fullard JF, Giakoumaki SG, et al. The relationship between dopamine receptor D1 and cognitive performance. NPJ Schizophr 2015; 1(1): 1-6.
[50]
Speranza L, di Porzio U, Viggiano D, de Donato A, Volpicelli F. Dopamine: The neuromodulator of long-term synaptic plasticity, reward and movement control. Cells 2021; 10: 735.
[52]
Duszkiewicz AJ, McNamara CG, Takeuchi T, Genzel L. Novelty and dopaminergic modulation of memory persistence: A tale of two systems. Trends Neurosci 2019; 42: 102-4.
[59]
Moser EI, Moser MB, McNaughton BL. Spatial representation in the hippocampal formation: A history. Nat Neurosci 2017; 20: 1448-64.
[61]
Kaur S, DasGupta G, Singh S. ltered neurochemistry in Alzheimer’s disease: Targeting neurotransmitter receptor mechanisms and therapeutic strategy. Neurophysiology 2019; 51: 293-309.
[68]
Escartin C, Galea E, Lakatos A, et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci 2021; 24: 312-25.
[70]
Li K, Li J, Zheng J, Qin S. Reactive astrocytes in neurodegenerative diseases. Aging Dis 2019; 10: 664-75.
[79]
Colombo E, Farina C. Astrocytes: Key regulators of neuroinflammation. Trends in Immunology. Elsevier 2016; 37: pp. 608-20.
[81]
Ceyzériat K, Abjean L, Carrillo-de Sauvage MA, Ben Haim L, Escartin C. The complex STATes of astrocyte reactivity: How are they controlled by the JAK-STAT3 pathway? Neuroscience 2016; 330: 205-18.
[83]
Liddelow SA, Barres BA. Reactive astrocytes: Production, function, and therapeutic potential. Immunity Cell Press 2017; 46: 957-67.
[85]
Sofroniew MV. Astrocyte barriers to neurotoxic inflammation. Nat Rev Neurosci 2015; 16: 249-63.
[86]
Sofroniew MV. Astrocyte reactivity: Subtypes, states, and functions in CNS innate immunity. Trends Immunol 2020; 41: 758-70.
[87]
Geyer S, Jacobs M, Hsu NJ. Immunity against bacterial infection of the central nervous system: An astrocyte perspective. Front Mol Neurosci 2019; 12: 57.
[89]
Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol 2020; 20: 95-112.
[90]
Nie L, Cai SY, Shao JZ, Chen J. Toll-Like receptors, associated biological roles, and signaling networks in non-mammals. Front Immunol 2018; 9: 1523.
[97]
Sanz P, Garcia-Gimeno MA. Reactive glia inflammatory signaling pathways and epilepsy. Int J Mol Sci 2020; 21: 1-17.
[99]
Famakin BM, Vemuganti R. Toll-Like receptor 4 signaling in focal cerebral ischemia: A focus on the neurovascular unit. Mol Neurobiol 2020; 57: 2690-701.
[107]
Wu Y, Zhou BP. TNF-α/NFκ-B/Snail pathway in cancer cell migration and invasion. Br J Cancer 2010; 102: 639-44.
[108]
Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease. Ann Transl Med 2015; 3(10): 136.
[111]
Cosarderelioglu C, Nidadavolu LS, George CJ, et al. Brain renin–angiotensin system at the intersect of physical and cognitive frailty. Front Neurosci Frontiers Media SA 2020; 14.
[115]
Goldman B. Scientists reveal how beta-amyloid may cause Alzheimer’s. Standford Medicine News Center 2013; pp. 2013-6.
[118]
Azam S, Jakaria M, Kim IS, Kim J, Ezazul Haque M, Choi DK. Regulation of toll-like receptor (TLR) signaling pathway by polyphenols in the treatment of age-linked neurodegenerative diseases: Focus on TLR4 signaling. Front Immunol 2019; 10: 1000.
[119]
Abg Abd Wahab DY, Gau CH, Zakaria R, Muthu Karuppan MK, A-Rahbi BS, Abdullah Z. Review on cross talk between neurotransmitters and neuroinflammation in striatum and cerebellum in the mediation of motor behaviour. BioMed Res Int 2019; 2019: 1767203.
[122]
Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduction Targeted Ther 2017; 2: 1-9.
[124]
Sun SC. The non-canonical NF-κB pathway in immunity and inflammation. Nat Rev Immunol 2017; 17: 545-58.
[126]
Snow WM, Albensi BC. Neuronal gene targets of NF-κB and their dysregulation in alzheimer’s disease. Front Mol Neurosci 2016; 9: 118.
[130]
Zhang X, Xu A, Lv J, et al. Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseas-es. Eur J Med Chem 2020; 185: 111822.
[131]
Yang Y, Wang H, Kouadir M, Song H, Shi F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis 2019; 10(2): 128.
[132]
Guan Y, Han F. Key mechanisms and potential targets of the NLRP3 inflammasome in neurodegenerative diseases. Front Integr Neurosci 2020; 14: 37.
[133]
Wang S, Yuan YH, Chen NH, Wang HB. The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson’s disease. Int Immunopharmacol 2019; 67: 458-64.
[134]
Swanson KV, Deng M, Ting JPY. The NLRP3 inflammasome: Molecular activation and regulation to therapeutics. Nat Rev Immunol 2019; 19: 477-89.
[135]
Haque ME, Akther M, Jakaria M, Kim IS, Azam S, Choi DK. Targeting the microglial NLRP3 inflammasome and its role in Parkinson’s disease. Mov Disord 2020; 35: 20-33.
[136]
Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: An overview of mechanisms of activation and regulation. Int J Mol Sci 2019; 20(13): 3328.
[137]
Biasizzo M, Kopitar-Jerala N. Interplay between NLRP3 inflammasome and autophagy. Front Immunol 2020; 11: 591803.
[141]
Feng YS, Tan ZX, Wu LY, Dong F, Zhang F. The involvement of NLRP3 inflammasome in the treatment of Alzheimer’s disease. Ageing Res Rev 2020; 64: 101192.
[151]
Yang J, Wise L, Fukuchi KI. TLR4 cross-talk with NLRP3 inflammasome and complement signaling pathways in alzheimer’s disease. Front Immunol 2020; 11.
[173]
Fan H, Luttrell LM, Tempel GE, Senn JJ, Perry V, Cook JA. β-Arrestins 1 and 2 differentially regulate LPS-induced signaling. Mol Immunol 2007; 44(12): 3092-9.
[182]
Campos J, Pacheco R. Involvement of dopaminergic signaling in the cross talk between the renin-angiotensin system and inflammation. Semin Immunopathol 2020; 42: 681-96.
[195]
Nolan RA, Reeb KL, Rong Y, et al. Dopamine activates NF-κB and primes the NLRP3 inflammasome in primary human macrophages. Brain, Behav Immun - Heal 2020; 2: 100030.